QPPV.COM KNOWLEDGE ASSESSMENT

Tramadol: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Tramadol: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient taking tramadol has inadequate analgesia, and testing identifies reduced CYP2D6 activity. Which interpretation is most appropriate?
Question 2 of 10 A historical review cites an early patent, a commercial launch and a national authorisation as milestones in tramadol's development. What is the most appropriate way to interpret these dates?
Question 3 of 10 An aggregate review finds more spontaneous reports of tramadol-associated seizures this year than last year. What is the best initial interpretation?
Question 4 of 10 A patient has a reported CYP2D6 phenotype, but the case file lacks the test method, interacting medicines and exposure chronology. What is the most appropriate assessment?
Question 5 of 10 A patient taking tramadol with a benzodiazepine becomes unresponsive. Which follow-up best supports assessment of possible opioid respiratory depression?
Question 6 of 10 Which description best captures why tramadol should not be treated as either a conventional opioid alone or an inactive-parent prodrug?
Question 7 of 10 A case involves a French immediate-release capsule, but the company has a defined reference safety information document for expectedness. What should govern the operational expectedness assessment?
Question 8 of 10 A patient has been stable on tramadol while taking a CYP2D6 inhibitor. The inhibitor is discontinued. What pharmacokinetic change warrants particular attention?
Question 9 of 10 A team proposes applying a US opioid REMS requirement as a mandatory EU risk-minimisation measure. Which response is most appropriate?
Question 10 of 10 A pharmacist is considering CYP2D6 testing before tramadol treatment. Which statement best reflects the role of CPIC guidance described in the article?

Select an answer to continue.

QPPV.com